Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCHIX:CEVIS 97 3-Year Book Growth Rate is 11.40% as of Jun. 2026, which is 36% below its 10-year median of 17.70. GuruFocus rates CHIX:CEVIS with a GF Score™ of 97/100 and a GF Value™ of kr187.28. The stock has 2 warning signs investors should review. Among 758 Medical Devices & Instruments companies, CellaVision AB ranks better than 77.31% on this metric.
During the past 12 months, CellaVision AB's average Book Value per Share Growth Rate was 7.70% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 11.40% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 15.20% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 18.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of CellaVision AB was 78.10% per year. The lowest was 5.30% per year. And the median was 17.70% per year.
CellaVision AB (CHIX:CEVIs) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
CellaVision AB 3-Year Book Growth Rate Related Terms
CHIX:CEVIS vs ABT, SYK, MDT: 3-Year Book Growth Rate Comparison
For the Medical Devices subindustry, CellaVision AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB 3-Year Book Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where CellaVision AB's 3-Year Book Growth Rate falls into.
CellaVision AB 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 11.40% mean?
CellaVision AB (CHIX:CEVIS) has a 3-Year Book Growth Rate of 11.40% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for CellaVision AB and its competitors. This is 36% below median its historical median of 17.70. Over the past decade, CellaVision AB's 3-Year Book Growth Rate has ranged from 5.30 to 78.10. According to the industry distribution chart, CellaVision AB ranks #172 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 22.7%.
Is CellaVision AB's 3-Year Book Growth Rate too high?
CellaVision AB's current 3-Year Book Growth Rate of 11.40% is 36% below median its 10-year median of 17.70. Over the past 10 years, this metric has ranged from a low of 5.30 to a high of 78.10. The Medical Devices & Instruments industry median 3-Year Book Growth Rate is 2.40. CellaVision AB's value of 11.40% is 375% above this industry median. Based on the distribution chart, CellaVision AB ranks #172 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's 3-Year Book Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #172 out of 758 companies for 3-Year Book Growth Rate. This places CellaVision AB in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 2.40. CellaVision AB's value of 11.40% is 375% above this benchmark. Historically, CellaVision AB's own 3-Year Book Growth Rate has ranged from 5.30 to 78.10 over the past decade. While the company's 10-year median is 17.70 vs. the industry median of 2.40, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.40, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current 3-Year Book Growth Rate of 11.40% is 375% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current 3-Year Book Growth Rate is 11.40%, which is 36% below median its own 10-year median of 17.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current 3-Year Book Growth Rate of 11.40%. The stock's GF Value™ is kr187.28, compared to a current price of kr160.20 — trading 14.5% below its estimated fair value. The current 3-Year Book Growth Rate is 11.40%, which is 36% below median its 10-year median of 17.70 and 375% above the Medical Devices & Instruments industry median of 2.40. CellaVision AB's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current 3-Year Book Growth Rate is 11.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 14.5% below its estimated GF Value™ of kr187.28.
Key valuation signals for CHIX:CEVIS:
3-Year Book Growth Rate: 11.40% (36% below median its 10-year median of 17.70)
GF Value™: kr187.28 vs. price of kr160.20 (14.5% below fair value)
Industry Position: 375% above the Medical Devices & Instruments median (#172 of 758)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
97GF Score
Get the complete analysis for CHIX:CEVIS
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
